Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011
Tue, November 15, 2011
Mon, November 14, 2011
[ Mon, Nov 14th 2011 ] - Market Wire
30 AM Eastern Time
Sun, November 13, 2011
Sat, November 12, 2011
Fri, November 11, 2011
Thu, November 10, 2011

International Stem Cell to Hold Business Update Conference Call on November 17


//health-fitness.news-articles.net/content/2011/ .. iness-update-conference-call-on-november-17.html
Published in Health and Fitness on Wednesday, November 16th 2011 at 9:45 GMT by Market Wire   Print publication without navigation


CARLSBAD, Calif.--([ ])--International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Thursday, November 17, 2011 at 1:00 p.m. Eastern (10:00 a.m. Pacific). President and Chief Operating Officer Kurt May and Co-Chairman Ken Aldrich will provide an update on the business, including a discussion of recently announced third quarter results.

Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Companyas Web site at [ www.intlstemcell.com ].

A telephone replay will be available approximately one hour after the conclusion of the call by dialing (877) 660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 383602. The webcast will be available on the Companyas Web site for 60 days following the completion of the call.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCella". ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at [ www.internationalstemcell.com ].

To subscribe to receive ongoing corporate communications, please click on the following link: [ http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 ].


Publication Contributing Sources